The Impact of Hormonal Changes on Diabetic Eye Disease in Women

Diabetic eye disease, particularly diabetic retinopathy, remains a leading cause of preventable blindness among adults of working age. While both men and women with diabetes face this threat, emerging evidence highlights a critical sex-specific factor: hormonal fluctuations across a woman’s lifespan can profoundly influence the onset and progression of diabetic eye complications. Understanding this interplay is not merely academic—it offers actionable pathways for more personalized screening, prevention, and treatment strategies that address the unique biology of women.

Understanding Diabetic Eye Disease

Diabetic eye disease encompasses several ocular complications of diabetes, including diabetic retinopathy, diabetic macular edema (DME), cataracts, and glaucoma. The most common and visually significant is diabetic retinopathy, a progressive disorder of the retinal microvasculature driven by chronic hyperglycemia. High blood sugar damages the endothelial cells lining the retinal capillaries, leading to capillary closure, retinal ischemia, and the release of vascular endothelial growth factor (VEGF). This cascade prompts the growth of abnormal, leaky blood vessels—a condition known as proliferative diabetic retinopathy (PDR)—which can hemorrhage into the vitreous, cause retinal detachment, and ultimately result in severe vision loss.

DME, a companion condition where fluid accumulates in the macula, can occur at any stage of retinopathy and is a primary cause of vision impairment in people with diabetes. Globally, diabetic retinopathy affects approximately one-third of people with diabetes, and it remains the leading cause of new cases of blindness in adults aged 20–74 years in developed nations. Risk factors include duration of diabetes, poor glycemic control, hypertension, dyslipidemia, and pregnancy. Women with diabetes face additional risk modifiers related to hormonal status, especially during reproductive years and menopausal transition.

The Pathophysiology of Hormonal Influence on the Retina

Sex hormones—primarily estrogen and progesterone—exert significant effects on vascular function, inflammation, and glucose metabolism. Estrogen is vasoprotective: it enhances endothelial nitric oxide production, promotes vasodilation, reduces oxidative stress, and stabilizes the blood–retinal barrier. Progesterone can modulate insulin sensitivity and vascular permeability. When these hormones fluctuate rapidly or decline, the protective vascular effects are diminished, and the retinal microcirculation becomes more vulnerable to hyperglycemic damage. Beyond the retina, estrogen receptors (ERα and ERβ) are expressed in the choroid and retinal pigment epithelium, suggesting direct hormonal modulation of ocular structures.

These shifts are not uniform; they occur in predictable life stages—menstruation, pregnancy, and menopause—and also in response to exogenous hormones such as oral contraceptives or hormone replacement therapy (HRT). Each stage carries distinct implications for diabetic retinopathy risk and progression. Moreover, the interplay between hormones and inflammatory cytokines may explain why some women experience rapid worsening of retinopathy during periods of hormonal upheaval.

The Menstrual Cycle and Retinal Vulnerability

During the normal menstrual cycle, estrogen peaks in the follicular phase and again just before ovulation, while progesterone rises after ovulation. Studies have documented changes in retinal blood flow, choroidal thickness, and intraocular pressure across the cycle. For women with diabetes, these cyclical hormone swings can create temporary instability in blood sugar control, often manifesting as perimenstrual hyperglycemia. The combination of fluctuating glucose and altered retinal hemodynamics may increase the likelihood of microaneurysm formation and retinal hemorrhages, though more longitudinal data are needed to establish a causal link.

Clinical implication: Women who notice cyclical visual changes or worsening of diabetic control around their menstrual period should discuss this with their endocrinologist and eye care specialist. More frequent monitoring during certain phases of the cycle may be warranted. Continuous glucose monitoring (CGM) can help identify patterns that correlate with menstrual phases, allowing for preemptive adjustments in insulin or oral medications.

Pregnancy and the Accelerated Risk of Retinopathy

Pregnancy induces profound hormonal shifts: estrogen and progesterone rise dramatically, while insulin resistance increases due to placental hormones like human placental lactogen. For women with preexisting diabetes, this physiologic insulin resistance often necessitates aggressive glycemic management. However, rapidly improving glycemic control during pregnancy—especially in the first trimester—can paradoxically worsen diabetic retinopathy in the short term, a phenomenon known as “early worsening.” The underlying mechanism involves a sudden reduction in blood glucose levels that disrupts the fragile retinal circulation, leading to increased leakage and neovascularization.

Women with preexisting diabetic retinopathy are at highest risk of progression during pregnancy. Studies indicate that up to 30% of women with moderate to severe nonproliferative retinopathy will advance to proliferative disease or develop diabetic macular edema during gestation. Gestational diabetes mellitus (GDM), while less strongly associated with retinopathy than preexisting diabetes, still elevates the long-term risk of developing diabetic eye disease, particularly in women who later progress to type 2 diabetes.

Management recommendations: Women with diabetes should undergo a comprehensive dilated eye examination before pregnancy or as early as possible in the first trimester. Follow-up examinations should occur every trimester and again at 12 months postpartum. Tight glycemic control is essential but must be achieved gradually to minimize early worsening. Laser photocoagulation and intravitreal anti-VEGF therapy can be used during pregnancy for severe cases, though careful risk–benefit consideration is required. Additionally, blood pressure management becomes even more critical, as pregnancy-induced hypertension can exacerbate retinopathy.

Menopause and the Loss of Vascular Protection

The menopausal transition brings a sharp decline in estrogen production. This loss of vasoprotective signaling is associated with increased arterial stiffness, endothelial dysfunction, and systemic inflammation—all of which can exacerbate diabetic microvascular complications. Postmenopausal women with diabetes appear to have a higher prevalence of proliferative diabetic retinopathy than premenopausal women matched for age and diabetes duration. Additionally, diabetic macular edema may become more refractory to treatment in the postmenopausal setting.

Important nuance: Hormone replacement therapy (HRT) has been investigated as a potential modifier of retinopathy risk. Some observational studies suggest that women using HRT have a lower incidence of diabetic retinopathy, but the evidence is mixed, and randomized controlled trials are lacking. HRT is not currently recommended solely for the prevention or treatment of diabetic eye disease due to systemic risks (e.g., thromboembolic events, breast cancer). The decision to use HRT should be individualized, weighing cardiovascular and bone health benefits against potential harms—and always under the guidance of a primary care provider or gynecologist. Newer formulations, such as transdermal estradiol with micronized progesterone, may offer a more favorable risk profile for women with diabetes.

Other Hormonal Considerations

Polycystic Ovary Syndrome (PCOS)

PCOS, characterized by hyperandrogenism, insulin resistance, and anovulation, affects up to 10% of reproductive-age women. Women with PCOS have a higher risk of developing type 2 diabetes and, consequently, diabetic retinopathy. The chronic insulin resistance and compensatory hyperinsulinemia in PCOS may independently contribute to retinal vascular damage, even before frank diabetes develops. Early screening for diabetes and retinopathy is recommended for women with PCOS, especially those with additional risk factors such as obesity or a family history of diabetes. Lifestyle interventions, including weight loss and metformin therapy, can reduce diabetes risk and may have downstream benefits for eye health.

Oral Contraceptives and Hormonal Contraception

Combined oral contraceptives (estrogen–progestin) can affect glucose tolerance and insulin sensitivity, particularly with older, higher-dose formulations. Modern low-dose pills have minimal impact on diabetes risk but may still influence retinal health in women with preexisting diabetic retinopathy. Progestin-only contraceptives do not appear to carry similar concerns. Women with diabetes who use hormonal contraception should have regular blood pressure and blood glucose monitoring, as well as annual eye examinations. For women with active proliferative retinopathy or DME, ophthalmologists may recommend delaying initiation of combined hormonal contraceptives until the eye condition is stabilized.

Hormone Replacement Therapy and Fertility Treatments

Fertility treatments often involve supraphysiologic levels of estrogen and progesterone, which can lead to rapid changes in insulin sensitivity and fluid balance. Women with diabetes undergoing in vitro fertilization (IVF) should have a baseline eye exam and be monitored closely for any visual changes. Ovarian hyperstimulation syndrome, a complication of IVF, can cause thrombotic events and fluid shifts that may worsen retinopathy. Similarly, women using HRT for menopausal symptoms should have their eye exam status reviewed and be educated about potential visual side effects.

Management and Prevention Strategies Across Life Stages

An integrated, life-stage–oriented approach is essential for minimizing the impact of hormonal changes on diabetic eye disease. The following strategies should be embedded in routine diabetes care for women.

Customized Screening Schedules

The American Diabetes Association recommends yearly dilated eye examinations for all adults with diabetes, with more frequent examinations if retinopathy is present. For women, additional screening may be warranted during pregnancy, after the initiation or change of hormonal therapy, and perimenopausally. Patients with any visual symptoms—blurring, floaters, dark spots, or difficulty adapting to darkness—should be evaluated immediately regardless of their scheduled appointment. Emerging technologies such as artificial intelligence–based retinal screening may make frequent monitoring more accessible.

Optimized Glycemic Control with Hormonal Awareness

Blood glucose targets should be achievable and consistent. Women should be educated about potential glycemic variations during the menstrual cycle, pregnancy, and menopause. Continuous glucose monitoring (CGM) can help identify patterns that correlate with menstrual phases or HRT use. Insulin pump therapy may offer the flexibility needed to manage pregnancy-related glucose fluctuations. Postmenopausal women may require adjustments in their diabetes medications due to changes in renal function and insulin sensitivity. The use of GLP-1 receptor agonists and SGLT2 inhibitors has shown promise for both glycemic control and retinopathy protection, but prescribers must remain aware of rare risks such as DME development with certain GLP-1 agents; close ophthalmologic monitoring is recommended when initiating these therapies.

Vascular Health Management

Because diabetic retinopathy is a vascular disease, tight control of blood pressure and lipids is equally important. Angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs) are first-line therapies for hypertension in diabetes and may have additional retinal protective effects. Statins reduce the risk of cardiovascular events and may slow retinopathy progression in patients with dyslipidemia. Aspirin therapy, when indicated for cardiovascular prevention, does not increase the risk of retinal hemorrhage and can be used safely. Lifestyle measures such as regular exercise, smoking cessation, and a Mediterranean diet also contribute to vascular health.

Hormonal Therapy Decisions

For women with diabetes considering hormonal contraception, menopausal HRT, or fertility treatments, a multidisciplinary discussion involving endocrinology, ophthalmology, and gynecology is advisable. The impact on diabetic eye disease should be factored into the risk–benefit calculus, though it rarely outweighs other health considerations. For women with active proliferative retinopathy or diabetic macular edema, starting or changing hormonal therapy should ideally be delayed until the eye condition is stabilized. Postdoctoral evidence suggests that using non-oral routes of hormone delivery (transdermal, vaginal) may mitigate some of the metabolic effects.

Treatment Advances for Diabetic Eye Disease in Women

Intravitreal anti-VEGF therapies (e.g., ranibizumab, aflibercept, bevacizumab) remain the backbone of treatment for DME and PDR. Newer agents like faricimab, which inhibits both VEGF-A and angiopoietin-2, show extended durability—potentially reducing injection burden. For women with DME that is resistant to anti-VEGF, corticosteroids (e.g., dexamethasone implant, fluocinolone acetonide implant) can be effective, though they carry risks of cataract and intraocular pressure elevation—risks that may be influenced by hormonal status. Laser photocoagulation, once the standard of care, is now used more selectively, often as adjunctive therapy. Vitrectomy may be needed for advanced disease with vitreous hemorrhage or tractional retinal detachment.

Promising Research and Future Directions

Scientists are actively investigating how sex hormones and their receptors modulate retinal health at the molecular level. Estrogen receptors (ERα and ERβ) are expressed in the retina and choroid, raising the possibility of targeted hormonal interventions that could preserve retinal function without systemic side effects. Animal studies suggest that selective estrogen receptor modulators (SERMs) and even short-term estrogen therapy can reduce retinal capillary leakage and inflammation. Human clinical trials are still needed to translate these findings into practice.

Additionally, the role of progesterone in retinal protection is less understood but gaining attention. Progesterone may limit retinal edema by stabilizing the blood–retinal barrier and reducing VEGF expression. Future therapies might combine hormonal modulation with current anti-VEGF injections to extend treatment intervals and improve outcomes in women. Research into the retinal renin-angiotensin system also highlights potential sex differences in the progression of diabetic eye disease.

Genomic and epigenomic studies are also uncovering how hormonal environment can alter gene expression in the retina, potentially explaining why some women with excellent glycemic control still develop severe retinopathy. Personalized medicine approaches that integrate a woman’s hormonal profile, genetic susceptibility, and glycemic history may one day guide screening frequency and treatment selection with unprecedented precision. Large-scale registries and longitudinal studies, such as the Women’s Health Initiative and the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study, continue to provide valuable data on sex-specific differences in diabetic complications.

For additional information, readers may refer to the National Eye Institute’s diabetic retinopathy resource, the American Diabetes Association’s eye health page, the CDC’s guide to diabetes and vision loss, and the Foundation Fighting Blindness for emerging research updates.

Empowering Women Through Knowledge and Action

The intersection of hormonal changes and diabetic eye disease is a vivid reminder that diabetes care must be personalized. Women with diabetes are not simply “diabetic patients”—they are individuals experiencing a dynamic endocrine environment that can amplify or mitigate the ocular complications of their condition. By understanding the menstrual cycle’s subtle influences, preparing for pregnancy with coordinated medical support, and navigating menopause with proactive eye and vascular care, women can significantly reduce their risk of vision loss.

Healthcare providers must also evolve, moving beyond one-size-fits-all guidelines to incorporate hormonal assessments into routine diabetes eye care. Simple steps—asking about menstrual history, pregnancy plans, contraceptive use, and menopausal status—can uncover vulnerabilities and open doors to earlier intervention. Together, informed patients and attentive clinicians can turn the tide against diabetic eye disease, preserving sight and improving quality of life across every hormonal milestone a woman faces. Ongoing education, advocacy, and research will continue to refine these strategies, ensuring that every woman with diabetes has the tools to protect her vision for decades to come.